Altimmune (ALT) Long-Term Debt Issuances (2012 - 2025)

Altimmune (ALT) reported Long-Term Debt Issuances of $20.0 million for Q4 2025, up 562.52% quarter-over-quarter from $3.0 million in Q1 2017.

Altimmune (ALT) Long-Term Debt Issuances (2012 - 2025) Analysis & Trends

Altimmune (ALT) has 3 years of Long-Term Debt Issuances data on file, last reported at $20.0 million in Q4 2025.

Long-Term Debt Issuances for Q4 2025 came in at $20.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $20.0 million (changed N/A YoY), and the FY2025 annual result was $35.0 million, changed N/A from the prior year.
Long-Term Debt Issuances grew to $20.0 million in Q4 2025 per ALT's latest filing, from $3.0 million in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $20.0 million in Q4 2025 and troughed at $20.0 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	2.73 Mn
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Altimmune	336.67 Mn	336.67 Mn	-	-

Download Data